Anna Berkenblit, Chief Scientific and Medical Officer of Pancreatic Cancer Action Network, shared a post on LinkedIn:
“Yesterday’s announcement from Revolution Medicines that their RAS inhibitor daraxonrasib extends survival in pancreatic cancer marks a significant step forward. This milestone signals the beginning of a new era in treatment – bringing renewed hope to people facing this disease.
We are standing at the threshold of groundbreaking treatments for patients with pancreatic cancer.
Other articles featuring Anna Berkenblit.